movement disorder

(redirected from Extrapyramidal disorder)
Also found in: Wikipedia.

movement disorder

any of numerous neurological disorders characterized by disturbances of muscular movement, distinguished as either hyperkinetic (conditions such as chorea, dystonia, hemiballismus, myoclonus, stereotypy, tic, and tremor) or hypokinetic (conditions such as akinetic mutism, psychomotor retardation, and the stiff-man syndrome).

movement disorder

Any brain-based motor system disorder marked by disturbed muscle movement. These disorders include hemiplegia, ataxia, monoplegia, tremors, rigors, chorea, athetosis, convulsions, spasm (clonic or tonic), reflex (hysterical, habit spasm, tics), and spastic paralysis. Movement disorders are common in the elderly (e.g., those with degenerative neurological diseases). When they occur acutely, they are often caused by a new medication or toxin, stroke, or trauma.
See: hyperkinetic disorder; hypokinetic movement disorder
References in periodicals archive ?
Table 19: Incidence of EPS Compared to Placebo in the Adjunctive Therapy Bipolar Depression Studies Adverse Event Term Placebo LATUDA 20 to (N=334) 120 mg/day (%) (N=360)(%) All EPS events 13 24 Ail EPS events, 9 14 excluding Akathisia/Restlessness Akathisia 5 11 Dystonia* 1 1 Parkinsonism** 8 13 Restlessness 1 4 Note: Figures rounded to the nearest integer *Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus **Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor
The most common adverse reactions in clinical trials in patients with schizophrenia ([greater than or equal to]5% and twice placebo) were injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder.
The most common treatment-emergent adverse events (TEAEs)(3), that occurred at a rate of 10 percent or more were: extrapyramidal disorder (movement disorder) (25%), insomnia (14%), headache (12%), and akathisia (restlessness) (11%).
The most common adverse events were akathisia, extrapyramidal disorder, tremor, dyspepsia, and vomiting.
Cariprazine was generally well tolerated with the most common adverse events (10%) observed in any treatment group being akathisia, headache, insomnia, restlessness, and extrapyramidal disorder.
adverse reactions, defined by at least a 5% incidence and twice that of placebo, are injection site reactions, somnolence/sedation, dizziness, akathisia and extrapyramidal disorder.
The most commonly reported adverse reactions (5% and twice placebo), which were predominantly mild to moderate in severity, were akathisia, extrapyramidal disorder, dyspepsia, restlessness, tremor, fatigue and vomiting.
Across the cariprazine treated group, the most common adverse events (incidence >/=5% and greater than placebo) were nasopharyngitis, tremor, extrapyramidal disorder, akathisia, back pain, and blood creatine phosphokinase increased.
The most common adverse events (AEs) observed in any cariprazine dose group were insomnia, extrapyramidal disorder, akathisia, sedation, nausea, dizziness, and constipation.
The most common side effects that occurred with INVEGA(R) were restlessness and extrapyramidal disorder (for example, involuntary movements, tremors and muscle stiffness).
ADULTS: Nausea, vomiting, constipation, headache, dizziness, an inner sense of restlessness or need to move (akathisia), anxiety, insomnia, and restlessness -- PEDIATRIC PATIENTS (10 to 17 years): Extrapyramidal disorder (for example, uncontrolled movement disorders or muscle disturbances such as restlessness, tremors and muscle stiffness), headache, sleepiness, and nausea

Full browser ?